Eton Pharmaceuticals/$ETON
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
- Ticker
- $ETON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- Deer Park, United States
- Website
- www.etonpharma.com
ETON Metrics
BasicAdvanced
$1.9B
42.24
$1.60
0.83
-
Price and volume
Market cap
$1.9B
Beta
0.83
52-week high
$68.38
52-week low
$14.27
Average daily volume
600K
Financial strength
Current ratio
1.789
Quick ratio
1.517
Long term debt to equity
0.141
Total debt to equity
0.28
Interest coverage (TTM)
10.23%
Profitability
EBITDA (TTM)
49.135
Gross margin (TTM)
71.20%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
31.30%
Effective tax rate (TTM)
-34.54%
Revenue per employee (TTM)
$3,210,000
Management effectiveness
Return on assets (TTM)
21.08%
Return on equity (TTM)
90.62%
Valuation
Price to earnings (TTM)
42.24
Price to revenue (TTM)
13.23
Price to book
22.4
Price to tangible book (TTM)
45.66
Price to free cash flow (TTM)
93.342
Free cash flow yield (TTM)
1.07%
Free cash flow per share (TTM)
0.724
Growth
Revenue change (TTM)
100.61%
Earnings per share change (TTM)
-717.87%
3-year revenue growth (CAGR)
62.58%
3-year earnings per share growth (CAGR)
163.56%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Analyst projections of the future price of Eton Pharmaceuticals stock.
Bulls say / Bears say
Third-quarter product sales rose 158% year on year to $57.9 million, and Eton raised its 2026 revenue outlook to more than $175 million. Adjusted EBITDA margin reached 49% in the quarter, suggesting strong operating leverage as sales grow. (Eton Pharmaceuticals)
Eton reported record active-patient numbers across several key products, including INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, DESMODA and GALZIN. That breadth of demand supports further growth from products already on the market, rather than relying solely on future approvals. (Eton Pharmaceuticals)
Eton is adding potential growth drivers beyond its current portfolio: it licensed LIBERVANT for a planned neurology expansion and advanced several development programmes in the quarter. The KHINDIVI label-expansion filing was accepted for review, while the company says it expects to submit Amglidia for FDA review in the coming months. (Eton Pharmaceuticals, The Motley Fool)
Eton depends heavily on one specialty pharmacy: AnovoRx accounted for 93.8% of net product revenue in the first nine months of 2026. A disruption or loss of this customer could therefore have an outsized effect on sales and collections. (StockTitan)
The company relies on a small number of third-party suppliers to manufacture key ingredients and products. A significant supply interruption could disrupt both commercial sales and development programmes. (U.S. Securities and Exchange Commission)
ET-700’s pilot data showed a trade-off: treatment-related adverse events were lower than with GALZIN, but hepatic copper uptake fell by only 12%, versus 46% with GALZIN. Eton plans to test faster-release formulations, so the candidate still needs further work to show that it can combine tolerability with meaningful efficacy. (Eton Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
Upcoming events
No upcoming events
ETON News
AllArticlesVideos
Funds containing ETON
Fund name | Fund size | $ETON weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.12% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.06% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.